

# Urological Cancer Therapeutics Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

<https://marketpublishers.com/r/UE92EB5AB3AMEN.html>

Date: April 2018

Pages: 157

Price: US\$ 3,680.00 (Single User License)

ID: UE92EB5AB3AMEN

## Abstracts

### Report Summary

Urological Cancer Therapeutics Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Urological Cancer Therapeutics Drugs industry, standing on the readers' perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of Urological Cancer Therapeutics Drugs 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Urological Cancer Therapeutics Drugs worldwide and market share by regions, with company and product introduction, position in the Urological Cancer Therapeutics Drugs market

Market status and development trend of Urological Cancer Therapeutics Drugs by types and applications

Cost and profit status of Urological Cancer Therapeutics Drugs, and marketing status

Market growth drivers and challenges

The report segments the global Urological Cancer Therapeutics Drugs market as:

Global Urological Cancer Therapeutics Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)  
Asia Pacific (China, Japan, India, Southeast Asia and Australia)  
Latin America (Brazil, Argentina and Colombia)  
Middle East and Africa

Global Urological Cancer Therapeutics Drugs Market: Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Xofigo (radium Ra 223 dichloride)  
Jevtana (cabazitaxel)  
Inlyta (axitinib)  
Votrient (pazopanib hydrochloride)  
Sutent (sunitinib malate)  
Zytiga (abiraterone acetate)  
Xtandi (enzalutamide)  
Opdivo (nivolumab)  
Provenge (sipuleucel-T)

Global Urological Cancer Therapeutics Drugs Market: Application Segment Analysis  
(Consumption Volume and Market Share 2013-2023; Downstream Customers and  
Market Analysis)

Hospital  
Medical Research Laboratory  
Others

Global Urological Cancer Therapeutics Drugs Market: Manufacturers Segment Analysis  
(Company and Product introduction, Urological Cancer Therapeutics Drugs Sales  
Volume, Revenue, Price and Gross Margin):

Novartis  
Pfizer  
Johnson & Johnson  
AstraZeneca  
Astellas  
Bristol-Myers Squibb  
Abbott Laboratories  
Celgene Corporation  
Dendreon Corporation  
Ferring Pharmaceuticals  
GlaxoSmithKline plc  
Indevus Pharmaceuticals Inc

Ipsen  
Roche Healthcare  
Sanofi S.A.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF UROLOGICAL CANCER THERAPEUTICS DRUGS**

- 1.1 Definition of Urological Cancer Therapeutics Drugs in This Report
- 1.2 Commercial Types of Urological Cancer Therapeutics Drugs
  - 1.2.1 Xofigo (radium Ra 223 dichloride)
  - 1.2.2 Jevtana (cabazitaxel)
  - 1.2.3 Inlyta (axitinib)
  - 1.2.4 Votrient (pazopanib hydrochloride)
  - 1.2.5 Sutent (sunitinib malate)
  - 1.2.6 Zytiga (abiraterone acetate)
  - 1.2.7 Xtandi (enzalutamide)
  - 1.2.8 Opdivo (nivolumab)
  - 1.2.9 Provenge (sipuleucel-T)
- 1.3 Downstream Application of Urological Cancer Therapeutics Drugs
  - 1.3.1 Hospital
  - 1.3.2 Medical Research Laboratory
  - 1.3.3 Others
- 1.4 Development History of Urological Cancer Therapeutics Drugs
- 1.5 Market Status and Trend of Urological Cancer Therapeutics Drugs 2013-2023
  - 1.5.1 Global Urological Cancer Therapeutics Drugs Market Status and Trend 2013-2023
  - 1.5.2 Regional Urological Cancer Therapeutics Drugs Market Status and Trend 2013-2023

### **CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Development of Urological Cancer Therapeutics Drugs 2013-2017
- 2.2 Sales Market of Urological Cancer Therapeutics Drugs by Regions
  - 2.2.1 Sales Volume of Urological Cancer Therapeutics Drugs by Regions
  - 2.2.2 Sales Value of Urological Cancer Therapeutics Drugs by Regions
- 2.3 Production Market of Urological Cancer Therapeutics Drugs by Regions
- 2.4 Global Market Forecast of Urological Cancer Therapeutics Drugs 2018-2023
  - 2.4.1 Global Market Forecast of Urological Cancer Therapeutics Drugs 2018-2023
  - 2.4.2 Market Forecast of Urological Cancer Therapeutics Drugs by Regions 2018-2023

### **CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Sales Volume of Urological Cancer Therapeutics Drugs by Types
- 3.2 Sales Value of Urological Cancer Therapeutics Drugs by Types
- 3.3 Market Forecast of Urological Cancer Therapeutics Drugs by Types

## **CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Global Sales Volume of Urological Cancer Therapeutics Drugs by Downstream Industry
- 4.2 Global Market Forecast of Urological Cancer Therapeutics Drugs by Downstream Industry

## **CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 5.1 North America Urological Cancer Therapeutics Drugs Market Status by Countries
  - 5.1.1 North America Urological Cancer Therapeutics Drugs Sales by Countries (2013-2017)
  - 5.1.2 North America Urological Cancer Therapeutics Drugs Revenue by Countries (2013-2017)
  - 5.1.3 United States Urological Cancer Therapeutics Drugs Market Status (2013-2017)
  - 5.1.4 Canada Urological Cancer Therapeutics Drugs Market Status (2013-2017)
  - 5.1.5 Mexico Urological Cancer Therapeutics Drugs Market Status (2013-2017)
- 5.2 North America Urological Cancer Therapeutics Drugs Market Status by Manufacturers
- 5.3 North America Urological Cancer Therapeutics Drugs Market Status by Type (2013-2017)
  - 5.3.1 North America Urological Cancer Therapeutics Drugs Sales by Type (2013-2017)
  - 5.3.2 North America Urological Cancer Therapeutics Drugs Revenue by Type (2013-2017)
- 5.4 North America Urological Cancer Therapeutics Drugs Market Status by Downstream Industry (2013-2017)

## **CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 6.1 Europe Urological Cancer Therapeutics Drugs Market Status by Countries
  - 6.1.1 Europe Urological Cancer Therapeutics Drugs Sales by Countries (2013-2017)

- 6.1.2 Europe Urological Cancer Therapeutics Drugs Revenue by Countries (2013-2017)
- 6.1.3 Germany Urological Cancer Therapeutics Drugs Market Status (2013-2017)
- 6.1.4 UK Urological Cancer Therapeutics Drugs Market Status (2013-2017)
- 6.1.5 France Urological Cancer Therapeutics Drugs Market Status (2013-2017)
- 6.1.6 Italy Urological Cancer Therapeutics Drugs Market Status (2013-2017)
- 6.1.7 Russia Urological Cancer Therapeutics Drugs Market Status (2013-2017)
- 6.1.8 Spain Urological Cancer Therapeutics Drugs Market Status (2013-2017)
- 6.1.9 Benelux Urological Cancer Therapeutics Drugs Market Status (2013-2017)
- 6.2 Europe Urological Cancer Therapeutics Drugs Market Status by Manufacturers
- 6.3 Europe Urological Cancer Therapeutics Drugs Market Status by Type (2013-2017)
  - 6.3.1 Europe Urological Cancer Therapeutics Drugs Sales by Type (2013-2017)
  - 6.3.2 Europe Urological Cancer Therapeutics Drugs Revenue by Type (2013-2017)
- 6.4 Europe Urological Cancer Therapeutics Drugs Market Status by Downstream Industry (2013-2017)

## **CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 7.1 Asia Pacific Urological Cancer Therapeutics Drugs Market Status by Countries
  - 7.1.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Countries (2013-2017)
  - 7.1.2 Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Countries (2013-2017)
  - 7.1.3 China Urological Cancer Therapeutics Drugs Market Status (2013-2017)
  - 7.1.4 Japan Urological Cancer Therapeutics Drugs Market Status (2013-2017)
  - 7.1.5 India Urological Cancer Therapeutics Drugs Market Status (2013-2017)
  - 7.1.6 Southeast Asia Urological Cancer Therapeutics Drugs Market Status (2013-2017)
  - 7.1.7 Australia Urological Cancer Therapeutics Drugs Market Status (2013-2017)
- 7.2 Asia Pacific Urological Cancer Therapeutics Drugs Market Status by Manufacturers
- 7.3 Asia Pacific Urological Cancer Therapeutics Drugs Market Status by Type (2013-2017)
  - 7.3.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Type (2013-2017)
  - 7.3.2 Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Type (2013-2017)
- 7.4 Asia Pacific Urological Cancer Therapeutics Drugs Market Status by Downstream Industry (2013-2017)

## **CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

### 8.1 Latin America Urological Cancer Therapeutics Drugs Market Status by Countries

8.1.1 Latin America Urological Cancer Therapeutics Drugs Sales by Countries (2013-2017)

8.1.2 Latin America Urological Cancer Therapeutics Drugs Revenue by Countries (2013-2017)

8.1.3 Brazil Urological Cancer Therapeutics Drugs Market Status (2013-2017)

8.1.4 Argentina Urological Cancer Therapeutics Drugs Market Status (2013-2017)

8.1.5 Colombia Urological Cancer Therapeutics Drugs Market Status (2013-2017)

### 8.2 Latin America Urological Cancer Therapeutics Drugs Market Status by Manufacturers

### 8.3 Latin America Urological Cancer Therapeutics Drugs Market Status by Type (2013-2017)

8.3.1 Latin America Urological Cancer Therapeutics Drugs Sales by Type (2013-2017)

8.3.2 Latin America Urological Cancer Therapeutics Drugs Revenue by Type (2013-2017)

### 8.4 Latin America Urological Cancer Therapeutics Drugs Market Status by Downstream Industry (2013-2017)

## **CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

### 9.1 Middle East and Africa Urological Cancer Therapeutics Drugs Market Status by Countries

9.1.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Countries (2013-2017)

9.1.2 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Countries (2013-2017)

9.1.3 Middle East Urological Cancer Therapeutics Drugs Market Status (2013-2017)

9.1.4 Africa Urological Cancer Therapeutics Drugs Market Status (2013-2017)

### 9.2 Middle East and Africa Urological Cancer Therapeutics Drugs Market Status by Manufacturers

### 9.3 Middle East and Africa Urological Cancer Therapeutics Drugs Market Status by Type (2013-2017)

9.3.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Type (2013-2017)

9.3.2 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Type

(2013-2017)

9.4 Middle East and Africa Urological Cancer Therapeutics Drugs Market Status by Downstream Industry (2013-2017)

## **CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS**

10.1 Global Economy Situation and Trend Overview

10.2 Urological Cancer Therapeutics Drugs Downstream Industry Situation and Trend Overview

## **CHAPTER 11 UROLOGICAL CANCER THERAPEUTICS DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS**

11.1 Production Volume of Urological Cancer Therapeutics Drugs by Major Manufacturers

11.2 Production Value of Urological Cancer Therapeutics Drugs by Major Manufacturers

11.3 Basic Information of Urological Cancer Therapeutics Drugs by Major Manufacturers

11.3.1 Headquarters Location and Established Time of Urological Cancer Therapeutics Drugs Major Manufacturer

11.3.2 Employees and Revenue Level of Urological Cancer Therapeutics Drugs Major Manufacturer

11.4 Market Competition News and Trend

11.4.1 Merger, Consolidation or Acquisition News

11.4.2 Investment or Disinvestment News

11.4.3 New Product Development and Launch

## **CHAPTER 12 UROLOGICAL CANCER THERAPEUTICS DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

12.1 Novartis

12.1.1 Company profile

12.1.2 Representative Urological Cancer Therapeutics Drugs Product

12.1.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Novartis

12.2 Pfizer

12.2.1 Company profile

12.2.2 Representative Urological Cancer Therapeutics Drugs Product



12.2.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Pfizer

12.3 Johnson & Johnson

12.3.1 Company profile

12.3.2 Representative Urological Cancer Therapeutics Drugs Product

12.3.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson

12.4 AstraZeneca

12.4.1 Company profile

12.4.2 Representative Urological Cancer Therapeutics Drugs Product

12.4.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca

12.5 Astellas

12.5.1 Company profile

12.5.2 Representative Urological Cancer Therapeutics Drugs Product

12.5.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Astellas

12.6 Bristol-Myers Squibb

12.6.1 Company profile

12.6.2 Representative Urological Cancer Therapeutics Drugs Product

12.6.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb

12.7 Abbott Laboratories

12.7.1 Company profile

12.7.2 Representative Urological Cancer Therapeutics Drugs Product

12.7.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories

12.8 Celgene Corporation

12.8.1 Company profile

12.8.2 Representative Urological Cancer Therapeutics Drugs Product

12.8.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Celgene Corporation

12.9 Dendreon Corporation

12.9.1 Company profile

12.9.2 Representative Urological Cancer Therapeutics Drugs Product

12.9.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation

12.10 Ferring Pharmaceuticals

12.10.1 Company profile

- 12.10.2 Representative Urological Cancer Therapeutics Drugs Product
- 12.10.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceuticals
- 12.11 GlaxoSmithKline plc
  - 12.11.1 Company profile
  - 12.11.2 Representative Urological Cancer Therapeutics Drugs Product
  - 12.11.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
- 12.12 Indevus Pharmaceuticals Inc
  - 12.12.1 Company profile
  - 12.12.2 Representative Urological Cancer Therapeutics Drugs Product
  - 12.12.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Indevus Pharmaceuticals Inc
- 12.13 Ipsen
  - 12.13.1 Company profile
  - 12.13.2 Representative Urological Cancer Therapeutics Drugs Product
  - 12.13.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Ipsen
- 12.14 Roche Healthcare
  - 12.14.1 Company profile
  - 12.14.2 Representative Urological Cancer Therapeutics Drugs Product
  - 12.14.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Roche Healthcare
- 12.15 Sanofi S.A.
  - 12.15.1 Company profile
  - 12.15.2 Representative Urological Cancer Therapeutics Drugs Product
  - 12.15.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A.

## **CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS**

- 13.1 Industry Chain of Urological Cancer Therapeutics Drugs
- 13.2 Upstream Market and Representative Companies Analysis
- 13.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS**

- 14.1 Cost Structure Analysis of Urological Cancer Therapeutics Drugs
- 14.2 Raw Materials Cost Analysis of Urological Cancer Therapeutics Drugs
- 14.3 Labor Cost Analysis of Urological Cancer Therapeutics Drugs
- 14.4 Manufacturing Expenses Analysis of Urological Cancer Therapeutics Drugs

## **CHAPTER 15 REPORT CONCLUSION**

## **CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE**

- 16.1 Methodology/Research Approach
  - 16.1.1 Research Programs/Design
  - 16.1.2 Market Size Estimation
  - 16.1.3 Market Breakdown and Data Triangulation
- 16.2 Data Source
  - 16.2.1 Secondary Sources
  - 16.2.2 Primary Sources
- 16.3 Reference

## I would like to order

Product name: Urological Cancer Therapeutics Drugs-Global Market Status & Trend Report 2013-2023  
Top 20 Countries Data

Product link: <https://marketpublishers.com/r/UE92EB5AB3AMEN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UE92EB5AB3AMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

